MXPA04000041A - Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4. - Google Patents

Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4.

Info

Publication number
MXPA04000041A
MXPA04000041A MXPA04000041A MXPA04000041A MXPA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A MX PA04000041 A MXPA04000041 A MX PA04000041A
Authority
MX
Mexico
Prior art keywords
formula
compounds
vla
cell
antagonists
Prior art date
Application number
MXPA04000041A
Other languages
English (en)
Inventor
Wehner Volkmar
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA04000041A publication Critical patent/MXPA04000041A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a derivados novedosos de imidazolidina de la formula (I), en donde B, E, W, Y, R, R2, R3, R30, e y h tienen los significados indicados en las reivindicaciones. Los compuestos de la formula (I) son compuestos farmaceuticos que son adecuados, por ejemplo, para el tratamiento de enfermedades inflamatorias como por ejemplo artritis reumatoide, o enfermedades alergicas. Los compuestos de la formula (I) son inhibidores de la adhesion y migracion de leucocitos y/o antagonistas de receptor de adhesion VLA-4, que pertenece al grupo de las integrinas. Son adecuados, en general, para tratar enfermedades causadas o asociadas con un grado indeseable de adhesion de leucocitos y/o migracion de leucocitos o en las cuales las interacciones celula-celula o celula-matriz, basadas en las interacciones de receptores VLA-4 con sus ligandos, desempenan una funcion. La invencion se refiere ademas a procedimientos para la preparacion de los compuestos (I), a su uso y a preparaciones farmaceuticas que comprenden compuestos de la formula (I).
MXPA04000041A 2001-08-01 2002-07-20 Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4. MXPA04000041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10137595A DE10137595A1 (de) 2001-08-01 2001-08-01 Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PCT/EP2002/008106 WO2003011288A1 (en) 2001-08-01 2002-07-20 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists

Publications (1)

Publication Number Publication Date
MXPA04000041A true MXPA04000041A (es) 2004-05-21

Family

ID=7693930

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000041A MXPA04000041A (es) 2001-08-01 2002-07-20 Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4.

Country Status (30)

Country Link
US (1) US6962937B2 (es)
EP (1) EP1414444B1 (es)
JP (1) JP4676697B2 (es)
KR (1) KR100910930B1 (es)
CN (1) CN1537000B (es)
AR (1) AR036349A1 (es)
AT (1) ATE391504T1 (es)
AU (1) AU2002328931B2 (es)
BR (1) BR0211535A (es)
CA (1) CA2455966C (es)
CO (1) CO5550452A2 (es)
DE (2) DE10137595A1 (es)
DK (1) DK1414444T3 (es)
ES (1) ES2301673T3 (es)
HK (1) HK1066166A1 (es)
HR (1) HRP20040108A2 (es)
HU (1) HUP0401406A3 (es)
IL (2) IL160093A0 (es)
MX (1) MXPA04000041A (es)
MY (1) MY133467A (es)
NO (1) NO326696B1 (es)
NZ (1) NZ530887A (es)
PE (1) PE20030348A1 (es)
PL (1) PL365396A1 (es)
PT (1) PT1414444E (es)
RS (1) RS6104A (es)
RU (1) RU2318815C2 (es)
TW (1) TWI325863B (es)
WO (1) WO2003011288A1 (es)
ZA (1) ZA200400194B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4617449B2 (ja) 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するn−ヒドロキシアミド誘導体
EP2093218A1 (en) * 2008-02-22 2009-08-26 Ruggero Fariello Arylalkyl substituted imidazolidinones
JP2011519926A (ja) * 2008-05-05 2011-07-14 ウィンスロップ−ユニバーシティー ホスピタル Cox阻害薬の心血管系リスク因子の改善方法
EP3326645B1 (en) 2010-10-25 2020-03-18 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (es)
DE4009506A1 (de) * 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
EP0626861B2 (en) 1992-01-13 2004-04-28 Biogen, Inc. Treatment for asthma
DK0625912T3 (da) 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
DE4308034A1 (de) * 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP0804237B8 (en) 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
CA2193828A1 (en) 1994-06-29 1996-01-11 Timothy P. Kogan Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
EP0796855B1 (de) * 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
AU3738597A (en) 1996-07-25 1998-02-20 Biogen, Inc. Molecular model for vla-4 inhibitors
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) * 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
JP4555468B2 (ja) 1997-10-31 2010-09-29 アベンテイス・フアルマ・リミテツド 置換アニリド
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
TR200003848T2 (tr) 1998-06-30 2001-06-21 Pfizer Products Inc. VLA-4'e bağlı hücre bağlanmasının peptidil olmayan önleyicileri.
AU1915399A (en) 1998-07-10 2000-02-01 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
US20030109497A1 (en) 2003-06-12
DK1414444T3 (da) 2008-08-04
DE10137595A1 (de) 2003-02-13
NO20040426L (no) 2004-03-26
ES2301673T3 (es) 2008-07-01
ATE391504T1 (de) 2008-04-15
IL160093A (en) 2009-05-04
TWI325863B (en) 2010-06-11
RS6104A (en) 2006-10-27
WO2003011288A1 (en) 2003-02-13
BR0211535A (pt) 2004-07-13
HUP0401406A3 (en) 2004-11-29
KR20040020076A (ko) 2004-03-06
EP1414444B1 (en) 2008-04-09
HK1066166A1 (en) 2005-03-18
CO5550452A2 (es) 2005-08-31
US6962937B2 (en) 2005-11-08
PE20030348A1 (es) 2003-05-14
JP4676697B2 (ja) 2011-04-27
PT1414444E (pt) 2008-05-27
AU2002328931B2 (en) 2008-04-24
PL365396A1 (en) 2005-01-10
MY133467A (en) 2007-11-30
CA2455966C (en) 2011-09-20
EP1414444A1 (en) 2004-05-06
HUP0401406A2 (hu) 2004-10-28
CN1537000A (zh) 2004-10-13
RU2318815C2 (ru) 2008-03-10
RU2004105966A (ru) 2005-06-27
NO326696B1 (no) 2009-02-02
KR100910930B1 (ko) 2009-08-06
CN1537000B (zh) 2010-05-12
ZA200400194B (en) 2005-03-14
IL160093A0 (en) 2004-06-20
AR036349A1 (es) 2004-09-01
NZ530887A (en) 2005-09-30
CA2455966A1 (en) 2003-02-13
DE60226032T2 (de) 2009-05-20
JP2005504033A (ja) 2005-02-10
HRP20040108A2 (en) 2004-06-30
DE60226032D1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
ATE455788T1 (de) Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
MY118313A (en) Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
MY118176A (en) Heterocycles as inhibitors of leucocyte adhesion and as vla-4-antagonists
MY123865A (en) Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
MY119617A (en) 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
MY121745A (en) 2,4-substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them.
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
BR9610422A (pt) Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina
YU14196A (sh) Estri i amidi di-supstituisanog 1,4-piperidina, postupci za njihovo dobijanje i farmakološke kompozicije koje ih sadrže
MY134191A (en) Novel 5-membered ring heterocycles, their preparation their use and pharmaceutical preparations comprising them
US20030004189A1 (en) Pharmaceutical uses and synthesis of nicotinanilide-N-oxides
MXPA04000041A (es) Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4.
YU70803A (sh) Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa
TR200103856T2 (tr) Naftiridin türevleri, bunların preparasyon işlemleri, kullanımları ve farmasötik kompozisyonlar.
TWI256386B (en) Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
SG146692A1 (en) Melanin concentrating hormone antagonists
TR200103858T2 (tr) Hücre yapışmasının önleyicileri olarak ikame edilmiş purin türevleri
MXPA05005340A (es) Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.
WO2008155594A3 (en) Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof
TH64558A (es)
TH42839A (th) เฮเทอโรไซเคิลชนิด 5 เมมเบอร์ริงชนิดใหม่, การเตรียมสารเหล่านั้น, การใช้สารเหล่านั้นและยาเตรียมทางเภสัชศาสตร์ที่ประกอบด้วยสารเหล่านั้น

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration